ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 45 of 114 for:    focused ultrasound | Recruiting, Not yet recruiting, Available Studies

MR Guided High Intensity Focused Ultrasound for Lumbar Back Pain

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02291978
Recruitment Status : Recruiting
First Posted : November 17, 2014
Last Update Posted : August 8, 2018
Sponsor:
Information provided by (Responsible Party):
Pejman Ghanouni, Stanford University

Brief Summary:
The primary purpose of this protocol is to assess the ExAblate 2100 MR guided high intensity focused ultrasound device as an intervention for treatment of facetogenic lower back pain.

Condition or disease Intervention/treatment Phase
Lumbar Facet Joint Pain Device: ExAblate 2100 Not Applicable

Detailed Description:
This is a single group, single arm, open/nonblinded, non-randomized study. The primary outcomes are safety and preliminary efficacy. The InSightec ExAblate 2100 MRgHIFU system is a non-invasive thermal ablation device fully integrated with an MR imaging system and used for the ablation of soft tissue and bone.The study will reach primary completion 12 months from the time the study opens to accrual.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 10 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Feasibility Study to Evaluate the Safety and Initial Effectiveness of MR Guided High Intensity Focused Ultrasound (MRgHIFU) in the Treatment of Facetogenic Lumbar Back Pain
Study Start Date : October 2014
Estimated Primary Completion Date : November 2020
Estimated Study Completion Date : November 2020

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Back Pain

Arm Intervention/treatment
Experimental: ExAblate 2100 Treatment
The ExAblate 2100 system will be used in the MRgHIFU treatment of lower back pain arising from facet joint arthritis.
Device: ExAblate 2100
The InSightec ExAblate 2100 MRgHIFU system is a non-invasive thermal ablation device fully integrated with an MR imaging system and used for the ablation of soft tissue and bone.




Primary Outcome Measures :
  1. Device Related Complications as a Measure of Safety [ Time Frame: 24 months ]
    Safety will be determined by evaluating for the incidence and severity of any device related complication from the treatment day visit through 24 months after treatment.


Secondary Outcome Measures :
  1. Pain Relief on the Visual Analog Scale [ Time Frame: 24 months ]
    Effectiveness will be determined by the level of pain relief, as measured by the NRS, and decrease in analgesic/opiate use.

  2. Quality of Life Improvement [ Time Frame: 24 months ]
    Effectiveness will be determined by improved quality of life, as measured by the Oswestry Disability Index.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   21 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Men and women > 21 years of age and who are skeletally mature
  2. Body mass index ≤ 30 kg/m2
  3. Patients who are able to understand and willing to sign a written informed consent document and able to attend all study visits
  4. Patients with at least 6 months of chronic lower back pain (LBP) localized to the midline or axial low back, with symptoms attributed to the facet joints on physical examination that have persisted despite conservative therapy. Conservative therapy is defined as systemic pain medications and anti-inflammatory medications, as well as physical therapy, such as massage, heating, hydrotherapy, and strengthening exercises.
  5. Patients with Numerical Rating Scale worst lumbar back pain score of at least 4 out of 10 over the 24 hours preceding the time of rating.
  6. Patients must have chronic LBP attributed to facet joints as demonstrated by MRI consistent with at least grade 2 facet joint arthritis, with corresponding abnormal activity at the facet joint on 18F-sodium fluoride PET-CT.
  7. Patients must have an analgesic response to either prior local anesthetic injection to the facet joint or to radiofrequency ablation of the facet joint, with relapse of pain.
  8. The targeted facet joint must be deeper than 10 mm from the skin

Exclusion Criteria:

  1. Patients with severe lumbar lordosis
  2. Patients with contraindication for MR imaging such as implanted metallic devices that are not MRI-safe, size limitations, claustrophobia. etc
  3. Patients with known intolerance or allergy to MR contrast agent (gadolinium chelates) including advanced kidney disease (GFR <30 mL/min/1.73 m2) or on dialysis
  4. Pregnant and nursing patients will be excluded from the study because of a contraindication to administering MRI contrast agents to these patients
  5. Patients with known intolerance or allergy to medications used for sedation (midazolam), analgesia (fentanyl), and local and regional anesthesia (lidocaine, bupivacaine, and ropivacaine)
  6. Patients with evidence of lumbosacral radiculopathy on MRI or physical exam findings, including radicular leg pain, or any neurologic deficit at or below the segmental level of the highest facet to be treated, including subjects with impaired sphincter control
  7. Patients with pain at another location that

    1. cannot be distinguished from lumbar back pain
    2. does not rate at least 2 points less in worst pain score compared to lumbar back pain
    3. requires the use of analgesics
  8. Patients with gross spinal instability on imaging
  9. Patients who have lumbar spinal stabilization hardware in place
  10. Target is:

    • NOT visible by non-contrast MRI, OR
    • NOT accessible to ExAblate device
  11. Individuals who are not able or willing to tolerate the required prolonged stationary position during treatment (can be up to 5 hrs of total table time)
  12. Patients with acute medical condition (e.g. pneumonia, sepsis) that is expected to hinder them from completing this study
  13. Patients with unstable cardiac status including:

    1. Unstable angina pectoris on medication
    2. Patients with documented myocardial infarction within six months of protocol entry
    3. Congestive heart failure requiring medication (other than diuretic)
    4. Patients on anti-arrhythmic drugs
  14. Patients with severe hypertension (diastolic BP > 100 on medication)
  15. Patients with severe hematologic, neurologic, or other uncontrolled disease (e.g. platelets < 50,000/microL, INR > 1.5)
  16. Patients who are taking anti-thrombotic medication
  17. Severe cerebrovascular disease (multiple CVAs or CVA within 6 months)
  18. Patients with inflammatory arthritides.
  19. Patients unable to communicate with the investigator and staff
  20. Patients seeking compensation for disability or work injury.
  21. Patients who are part of another trial testing other Investigational Agents

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02291978


Contacts
Contact: Kara Richardson 650-561-5237 kjr9@stanford.edu

Locations
United States, California
Stanford University Recruiting
Stanford, California, United States, 94305
Contact: Kara Richardson    650-561-5237    kjr9@stanford.edu   
Principal Investigator: Pejman Ghanouni, MD, PhD         
Sponsors and Collaborators
Stanford University
Investigators
Principal Investigator: Pejman Ghanouni, MD, PhD Stanford University

Responsible Party: Pejman Ghanouni, Assistant Professor of Radiology, Stanford University
ClinicalTrials.gov Identifier: NCT02291978     History of Changes
Other Study ID Numbers: 29163
First Posted: November 17, 2014    Key Record Dates
Last Update Posted: August 8, 2018
Last Verified: August 2018

Keywords provided by Pejman Ghanouni, Stanford University:
back pain
facet joint
spine

Additional relevant MeSH terms:
Back Pain
Arthralgia
Low Back Pain
Pain
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Joint Diseases
Musculoskeletal Diseases